# Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis

> **NCT00376012** · PHASE3 · UNKNOWN · sponsor: **Tuberculosis Research Centre, India** · enrollment: 300 (actual)

## Conditions studied

- Tuberculosis
- Human Immunodeficiency Virus Infections

## Interventions

- **DRUG:** Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
- **DRUG:** Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)

## Key facts

- **NCT ID:** NCT00376012
- **Lead sponsor:** Tuberculosis Research Centre, India
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-02
- **Primary completion:** 2007-09
- **Final completion:** 2008-09
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2008-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376012, "Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00376012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*